CStone Pharmaceuticals (2616)

Hong Kong
Currency in HKD
3.43
+0.12(+3.63%)
Closed
2616 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
3.233.45
52 wk Range
0.803.89
Key Statistics
Edit
Bid/Ask
3.41 / 3.43
Prev. Close
3.31
Open
3.35
Day's Range
3.23-3.45
52 wk Range
0.8-3.89
Volume
5.62M
Average Volume (3m)
4.39M
1-Year Change
259.78%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2616 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
4.63
Upside
+34.95%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

CStone Company Profile

CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company’s product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Its products also comprise CS1002, CS2006, CS3005, CS2007, CS2008, CS6001, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Suzhou, China.

Compare 2616 to Peers and Sector

Metrics to compare
2616
Peers
Sector
Relationship
P/E Ratio
−27.5x−14.0x−0.5x
PEG Ratio
−0.35−0.170.00
Price/Book
8.4x4.1x2.6x
Price / LTM Sales
8.6x12.6x3.0x
Upside (Analyst Target)
34.8%28.1%55.6%
Fair Value Upside
Unlock10.1%10.1%Unlock

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 4.63
(+34.95% Upside)

Earnings

Latest Release
Mar 25, 2023
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the CStone (2616) Stock Price Today?

The CStone stock price today is 3.43.

What Stock Exchange Does CStone Trade On?

CStone is listed and trades on the Hong Kong stock exchange.

What Is the Stock Symbol for CStone?

The stock symbol for CStone is "2616."

What Is the CStone Market Cap?

As of today, CStone market cap is 4.23B.

What is CStone Earnings Per Share?

The CStone EPS is -0.112.

From a Technical Analysis Perspective, Is 2616 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.